GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aptahem AB (XSAT:APTA) » Definitions » DeferredTaxAndRevenue

Aptahem AB (XSAT:APTA) DeferredTaxAndRevenue : kr0.00 Mil (As of Mar. 2025)


View and export this data going back to 2015. Start your Free Trial

What is Aptahem AB DeferredTaxAndRevenue?

Deferred Tax And Revenue represents the current portion of obligations, which is a liability that usually would have been paid but is now pas due.

Aptahem AB's current deferred tax and revenue for the quarter that ended in Mar. 2025 was kr0.00 Mil.

Aptahem AB DeferredTaxAndRevenue Historical Data

The historical data trend for Aptahem AB's DeferredTaxAndRevenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aptahem AB DeferredTaxAndRevenue Chart

Aptahem AB Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
DeferredTaxAndRevenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Aptahem AB Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
DeferredTaxAndRevenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Aptahem AB DeferredTaxAndRevenue Related Terms

Thank you for viewing the detailed overview of Aptahem AB's DeferredTaxAndRevenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Aptahem AB Business Description

Traded in Other Exchanges
N/A
Address
Norra Vallgatan 58, Malmo, SWE, 211 22
Aptahem AB develops aptamer-based drugs for the treatment of acute life-threatening conditions where coagulation and inflammation interact in the disease process. The company's main candidate Apta-1 is developed as an emergency medicine intended to prevent the occurrence of life-threatening organ and tissue damage in patients suffering from sepsis.

Aptahem AB Headlines

No Headlines